Quantitation of ceftetrame in human plasma and urine by high-performance liquid chromatography

Abstract

A method is described for quantifying ceftetrame, the acid metabolite of methylene (6 R,7 R)-7-[( Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido]-3-[(5-methyl-2H-tetrazol-2-yl)-methyl] -8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate pivalate, an orally active cephalosporin. Sodium benzylpenicillin is added to the plasma as the reference standard. The compounds are extracted from plasma or urine using a Bond Elut phenyl column. An aliquot of the methanol eluate is analyzed by high-performance liquid chromatography using a Waters Nova-Pak phenyl column and a UV detector set to 225 nm. The ratios of the peak heights for ceftetrame and sodium benzylpenicillin are calculated and converted to concentrations of analyte with calibration curves that are generated from the analysis of analyte-free plasma or urine fortified with various amounts of ceftetrame and a fixed amount of sodium benzylpenicillin. For plasma, the limit of quantitation for the assay is 0.48 μg/ml and the inter-assay precision (relative standard deviation) is 9.3%. For urine, the limit of quantitation for the assay is 19.1 μg/ml, and the inter-assay precision is 4.9%.